2016 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson’s Research
10th Annual Parkinson’s Disease Therapeutics Conference
October 24, 2016
New York, NY

CONFERENCE PROGRAM

7:45  BREAKFAST

8:30 – 9:00  WELCOME BY SOHINI CHOWDHURY AND JESSE CEDARBAUM, MD

9:00 – 10:15  PRIORITY TARGET 1: ALPHA-SYNUCLEIN

ARMIN GIESE, MD, MODAG GmbH
“Evaluation of the Oligomer Modulator anle138b”

HENRIK ZETTERBERG, MD, PhD, University of Gothenburg
“Investigating Synuclein Consortium Update: Alpha-Synuclein Assay Standardization Round Robin”

POUL HENNING JENSEN, MD, PhD, Aarhus University
“Characterization of MJFF Alpha-Synuclein Filament-specific Antibodies”

Q&A discussion for all

10:15 – 10:45  NETWORKING BREAK/POSTER VIEWING

10:45 – 12:00  PRIORITY TARGET 2: LRRK2

KALPANA MERCHANT, PhD, TransThera Consulting Co
“LRRK2 No Longer Lurking in Shadows: A Translational Plan to Deliver LRRK2 Kinase Inhibitors”

JEAN-MARC TAYMANS, PhD/IR, Jean-Pierre Aubert Research Center
“LRRK2 Detection Initiative: Characterization of the Detection of LRRK2 in Human Biofluids”

MATTHEW FELL, PhD, Merck Research Laboratories
“Characterization of Morphological Changes in Mouse Lung Following LRRK2 Kinase Inhibition”

Q&A discussion for all
12:00 – 1:00  LUNCH/POSTER VIEWING

1:00 – 2:15  EVOLVING APPROACHES TO PD INTERVENTION: FROM SURGERY TO GENETIC MODELING

DAVID CHARLES, MD, Vanderbilt University Medical Center
MALORY HACKER, PhD, Vanderbilt University Medical Center
“Is DBS Disease Modifying? Multicenter Clinical Trial of DBS in Early Stage Parkinson’s Disease”

MICHAEL OKUN, MD, AND AYSE GUNDOZ, PhD,
University of Florida Center for Movement Disorders and Neurorestoration
“Responsive, Closed-Loop Approach to Treat Freezing of Gait in PD”

GAIA SKIBINKSI, PhD, The J. David Gladstone Institute of Neurological Disease
“Developing a Human Preclinical Pipeline for Parkinson’s Disease”

2:15 – 2:45  NETWORKING BREAK/POSTER VIEWING

2:45 – 4:00  HOT TOPICS IN PARKINSON’S DISEASE RESEARCH

CLEMENS R. SCHERZER, MD, Harvard Medical School
“GBA: The New Hot PD Target”

KENNETH MAREK, MD, The Institute for Neurodegenerative Disorders
“Update on The Parkinson’s Progression Markers Initiative (PPMI) – Informing Future Drug Trials”

KARL KIEBURTZ, MD, MPH, University of Rochester Medical Center
“Future Clinical Trial Designs in Parkinson Disease: Segmentation and Adaptation”

4:00 – 4:15  CLOSING REMARKS

4:15 – 6:00  COCKTAIL RECEPTION/POSTER VIEWING